Regulation of B cell growth and differentiation via CD21 and CD40

被引：22

作者：

Axcrona, K ^{[1
]}

Gray, D ^{[1
]}

Leanderson, T ^{[1
]}

机构：

[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0HS,ENGLAND

来源：

EUROPEAN JOURNAL OF IMMUNOLOGY | 1996年 / 26卷 / 09期

基金：

英国惠康基金;

关键词：

B cell; CD21; CD40;

D O I：

10.1002/eji.1830260936

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Stimulation in vitro of murine splenic B cells by lipopolysaccharide, anti-kappa Sepharose, anti-CD40 or allo-reactive T helper cells all up-regulated CD21 and CD23 surface expression. Neither anti-CD21 nor anti-CD23 antibodies induced B cell growth or differentiation when added in soluble form or coupled to Sepharose. However, anti-CD40-stimulated B cells showed increased proliferation in the presence of anti-CD21 antibodies coupled to Sepharose; co-stimulation via CD21 also induced differentiation to immunoglobulin secretion in a fraction of anti-CD40-stimulated B cells. Furthermore, anti-CD40 antibodies inhibited differentiation to immunoglobulin secretion induced by lipopolysaccharide and, hence, appears to be a dominant negative signal for B cell differentiation.

引用

页码：2203 / 2207

页数：5

共 31 条

[1] INHIBITION OF MITOGENIC STIMULATION OF MOUSE LYMPHOCYTES BY ANTI-MOUSE IMMUNOGLOBULIN ANTIBODIES .1. MODE OF ACTION [J].

ANDERSSON, J ;

BULLOCK, WW ;

MELCHERS, F .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1974, 4 (11) :715-722

[2] THE CD40 LIGAND, GP39, IS DEFECTIVE IN ACTIVATED T-CELLS FROM PATIENTS WITH X-LINKED HYPER-IGM SYNDROME [J].

ARUFFO, A ;

FARRINGTON, M ;

HOLLENBAUGH, D ;

LI, X ;

MILATOVICH, A ;

NONOYAMA, S ;

BAJORATH, J ;

GROSMAIRE, LS ;

STENKAMP, R ;

NEUBAUER, M ;

ROBERTS, RL ;

NOELLE, RJ ;

LEDBETTER, JA ;

FRANCKE, U ;

OCHS, HD .

CELL, 1993, 72 (02) :291-300

[3]

BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969

[4] ACTIVATION OF HUMAN B-CELLS MEDIATED THROUGH 2 DISTINCT CELL-SURFACE DIFFERENTIATION ANTIGENS, BP35 AND BP50 [J].

CLARK, EA ;

LEDBETTER, JA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (12) :4494-4498

[5] EPSTEIN-BARR-VIRUS COMPLEMENT C3D RECEPTOR IS AN INTERFERON-ALPHA RECEPTOR [J].

DELCAYRE, AX ;

SALAS, F ;

MATHUR, S ;

KOVATS, K ;

LOTZ, M ;

LERNHARDT, W .

EMBO JOURNAL, 1991, 10 (04) :919-926

[6] C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity [J].

Dempsey, PW ;

Allison, MED ;

Akkaraju, S ;

Goodnow, CC ;

Fearon, DT .

SCIENCE, 1996, 271 (5247) :348-350

[7] ABNORMAL B-LYMPHOCYTE DEVELOPMENT, ACTIVATION, AND DIFFERENTIATION IN MICE THAT LACK OR OVEREXPRESS THE CD19 SIGNAL-TRANSDUCTION MOLECULE [J].

ENGEL, P ;

ZHOU, LJ ;

ORD, DC ;

SATO, S ;

KOLLER, B ;

TEDDER, TF .

IMMUNITY, 1995, 3 (01) :39-50

[8]

FINGEROTH JD, 1981, P NATL ACAD SCI USA, P4510

[9] A SOLUBLE FORM OF TRAP (CD40 LIGAND) IS RAPIDLY RELEASED AFTER T-CELL ACTIVATION [J].

GRAF, D ;

MULLER, S ;

KORTHAUER, U ;

VANKOOTEN, C ;

WEISE, C ;

KROCZEK, RA .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) :1749-1754

[10]

GRAMMER AC, 1995, J IMMUNOL, V154, P4996

← 1 2 3 4 →